OSE Immunotherapeutics Enhances Executive Leadership
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has made significant strides in its leadership structure by announcing two pivotal appointments aimed at propelling the company forward. In a strategic move, Fiona Olivier has stepped in as the Chief Corporate Affairs and Investor Relations Officer, while Aurore Morello, previously the Head of Research and Director of R&D Programs, has been elevated to the Executive Committee.
New Faces in Leadership Roles
The appointments of Fiona Olivier and Aurore Morello come at a crucial time for OSE Immunotherapeutics. Under the leadership of CEO Nicolas Poirier, both will play instrumental roles in shaping the strategic direction of the company while enhancing its core mission of developing innovative immunotherapeutic solutions.
Fiona Olivier's Background
With extensive experience across several global pharmaceutical entities, Fiona Olivier’s expertise encompasses communications, corporate affairs, and patient engagement. Having recently served as the Global Head of Corporate Affairs in the General Medicines division at Sanofi, she was responsible for communications during transformative projects, including major acquisitions. Fiona brings with her a compelling 30-year history in the field, having worked with renowned companies such as AbbVie, Abbott, and GSK. These experiences provide her with a comprehensive understanding of the market dynamics and patient needs.
Aurore Morello's Journey
Aurore Morello has been part of OSE Immunotherapeutics since 2016. She previously contributed her expertise from the Memorial Sloan Kettering Cancer Center, focusing on engineered CAR-T cell therapy. This solid foundational knowledge has been critical in advancing OSE’s research efforts in immunology. Aurore has displayed remarkable leadership in driving projects that translate immunological discoveries into practical drug candidates.
Farewell to a Founding Leader
The company also marks a poignant moment as it prepares to say farewell to Dominique Costantini, a co-founder and the former CEO. Dominique’s departure symbolizes a significant transition in OSE's history. She has been a driving force since the company’s inception, guiding its strategy and expansion. Nicolas Poirier acknowledged her contributions, emphasizing the mentorship she provided to many within the organization. The leadership team and staff express gratitude for her dedication and vision.
Vision for the Future
In their new roles, both Fiona and Aurore are poised to influence OSE Immunotherapeutics’ trajectory as it continues to strive for excellence in immuno-oncology and immuno-inflammation. Fiona’s insights will directly impact corporate communications and investor relations, ultimately enhancing company visibility and stakeholder engagement. Aurore’s commitment to scientific advancement positions her to lead innovative research projects that could pave the way for groundbreaking therapies.
Ongoing Commitment to Innovation
OSE Immunotherapeutics remains unwavering in its dedication to developing first-in-class immunotherapeutic solutions that meet the growing demands of patients and healthcare providers worldwide. As the company fortifies its executive team, it aims to strengthen partnerships with academic institutions and biopharmaceutical firms to drive transformative medicine.
About OSE Immunotherapeutics
OSE Immunotherapeutics is dedicated to pioneering therapeutic solutions in immunbiology, focusing on unmet patient needs. With a robust pipeline of first-in-class assets, OSE Immunotherapeutics partners with leading organizations to deliver innovative therapies aimed at treating serious diseases. The company is headquartered in France and is publicly traded on Euronext.
Frequently Asked Questions
What are the new roles for Fiona Olivier and Aurore Morello?
Fiona Olivier will serve as Chief Corporate Affairs and Investor Relations Officer, while Aurore Morello will continue on the Executive Committee, enhancing her role in research and development.
How does Fiona’s background benefit OSE Immunotherapeutics?
Fiona Olivier brings 30 years of experience in corporate affairs and communications from major global pharmaceutical companies, enhancing the company’s strategic vision.
What is the significance of Dominique Costantini's retirement?
Dominique Costantini's retirement marks a pivotal transition for OSE Immunotherapeutics, as she was a founding leader instrumental in the company’s development and strategy.
What is OSE Immunotherapeutics' mission?
The company aims to develop transformative immunotherapeutic solutions to meet unmet patient needs, focusing on immuno-oncology and immuno-inflammation.
How does the company plan to drive innovation?
By enhancing its executive team and continuing collaborations with academic and biopharmaceutical partners, OSE Immunotherapeutics aims to push the boundaries of science and advance healthcare solutions.
